Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -2.75 | $0 | -$2M |
| 2026 Q1 | -2.00 | $0 | -$349,691 |
| 2025 Q4 | -3.90 | $0 | -$422,010 |
| 2025 Q3 | -1.37 | $0 | -$610,045 |
| 2025 Q2 | -1.66 | $0 | — |
| 2025 Q1 | -1.50 | $0 | — |
| 2024 Q4 |
| 0.00 |
| $0 |
| — |
| 2024 Q3 | -2.79 | $0 | — |